Glioblastoma multiforme (GBM) is the highest grade of
astrocytoma. GBM pathogenesis has been linked to
receptor tyrosine kinases and
kinases further down signal-transduction pathways - in particular, members of the
protein kinase C (PKC) family. The expression and activity of various PKC
isoforms are increased in malignant
astrocytomas, but not in non-neoplastic astrocytes. This suggests that PKC activity contributes to
tumor progression. The level of
PKC-eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferation of two
glioblastoma cell lines, U-1242 MG and U-251 MG. Normally, U-1242 cells do not express
PKC-eta, and PMA inhibits their proliferation. Conversely, PMA increases proliferation of U-1242 cells that are stably transfected with
PKC-eta (U-1242-PKC-eta). PMA treatment also stimulates proliferation of U-251 cells, which express
PKC-eta. Here, we determined that
extracellular signal-regulated kinase (ERK) and Elk-1 are downstream targets of
PKC-eta. Elk-1-mediated transcriptional activity correlates with the
PKC-eta-mediated mitogenic response. Pretreatment of U-1242-PKC-eta cells with inhibitors of PKC or
MAPK/ERK kinase (
MEK) (bisindolyl
maleimide (BIM) or
U0126, respectively) blocked both PMA-induced Elk-1 transcriptional activity and PMA-stimulated proliferation. An overexpressed dominant-negative
PKC-eta reduced the mitogenic response in U-251 cells, as did reduction of Elk-1 by
small interfering RNA. Taken together, these results strongly suggest that
PKC-eta-mediated
glioblastoma proliferation involves
MEK/
mitogen-activated
protein (MAP)
kinase phosphorylation, activation of ERK and subsequently of Elk-1. Elk-1 target genes involved in GBM proliferative responses have yet to be identified.